Investing in Relay Medical Corp: A Covid-testing solution worth paying attention to

By Kirsteen Mackay


Relay Medical Corp's Fionet platform will help society return to a normal post-pandemic life with its rapid antigen testing ability.

Covid-testing company Relay Medical Corp. (CSE: RELA, OTC:RYMDF) has a sought after solution to the global travel restriction problem. With massive pressure on government and industry to get the economy moving again, Relay Medical’s testing kits are sure to prove a necessary asset in the nation’s fight against the virus.

This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically. A novel coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China in 2019. The illness caused by this virus has been named coronavirus disease 2019 (COVID-19).

Fighting Covid-19 with rapid testing – Photographer: CDC | Source: Unsplash

Relay Medical’s rapid testing solution

It’s becoming apparent that a co-ordinated, reliable, and effective testing program is essential to getting things opened and running smoothly again.
Relay Medical’s Fionet device is the ultimate solution because it can rapidly read lateral flow tests in minutes, and it can store that data securely so that users have updated health data at their fingertips to prove to themselves and those around them they are safe.

It’s expected that COVID infections will rapidly decline as vaccines work their magic, but for society to feel safe returning to a busy and interactive life, swift testing is vital.

Relay Medical’s Fionet device allows for hundreds of people to be tested with their results processed in an hour. Best of all, it doesn’t require special medical training, so anyone can operate it.

Many recognised and respected companies have been using the Fionet device for years. It’s been used extensively in testing for Ebola and Malaria in Africa. This gives it credibility and proof of work as it’s not a brand-new unknown.

Greater Toronto Airport leads the way

And the Greater Toronto Airports Authority (GTAA) is leading the way. As it begins implementing Fionet in its rapid COVID-19 point-of-need testing research. It’s launching a robust new COVID-19 PCR and antigen testing research program on March 1.

GTAA’s plan is to test the efficacy of antigen testing in comparison with rapid polymerase chain reaction (PCR) testing in a fast-paced and busy commercial environment where commuters share space.

The GTAA will work with Fionet Rapid Response Group (FRR). This is a joint venture between Fio Corporation and Relay Medical Corp. The FRR will deploy its digital workflow, testing, and data infrastructure for execution and oversight of this incredibly important airport program.

Trace and isolate at source

The ten-week study will make free COVID-19 tests available to employees. It will also provide testing for eligible passengers on select routes who are willing to volunteer as participants. Integration of various testing technologies, passenger processes, and all data flows will be managed by the Fionet Platform.

This research is going to go a long way in helping identify, trace and isolate Covid-19 at source, helping to reassure communities and give confidnce to travellers and workers.

Kevin Schwartz, infectious disease physician at Unity Health Toronto and the University of Toronto commented:

“Frequent, rapid testing for screening of asymptomatic people is an important layer among other essential public health measures to reduce the risk of spreading COVID-19. We are excited to be supporting the GTAA and their partners in evaluating rapid testing of employees to build on our current knowledge on how to safely and effectively implement these tools,”

Relay Medical’s testing device is proven and has had over $70 million spent on perfecting it. The company has improved the device with high-throughput software that ensures the testing and evaluation of multiple users really quickly.

Putting the pandemic behind us

Successfully emerging from the pandemic requires continuous testing at speed. It’s also important that it’s cost effective and proven. Thankfully, that’s exactly what Relay Medical’s Fionet platform provides.

While everyone is hopeful Covid-19 will soon be behind us, there’s no doubt we can’t become complacent. This is not the first pandemic the world has seen, and we can be sure it won’t be the last. If regular rapid testing can become a normalised part of life, it can help us stay safe for the long-term and help us isolate any future viral strains before they escalate out of control.

Person wearing a face mask on a call on their mobile phone

Emerging from the Covid-19 pandemic – Photographer: Engin Akyurt | Source: Unsplash

An exciting investment with massive growth potential

This is great from a potential investment point of view. The product is something for the long-term, not just the next few months. And for Relay Medical it’s also a money spinner. The company is paid per test taken.

Considering this has the potential to begin a widespread roll out to schools, churches, manufacturing plants, entertainment venues, nightclubs, pubs, sporting events, festivals etc, the possibility for scale is endless.

It’s also a very real and agreeable solution to getting the world back to enjoying a safe sense of normality.

The Fionet platform holds the key to a normal life. It reads all the data and can share this quickly and easily with the places you go, so that everyone can feel confident that they’re socialising or working in a virus-free zone.


In this article:

Author: Kirsteen Mackay

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Sign up for Investing Intel Newsletter